Articles from Seawolf Therapeutics
Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics
Seawolf Therapeutics (“Seawolf”) today announced its emergence from stealth, having raised $100 million to transform patient outcomes through the use of its proprietary DNA delivery platform.
By Seawolf Therapeutics · Via Business Wire · November 16, 2026